文献速递心血管CT

他汀类药物对冠状动脉粥样硬化斑块的影响:PARADIGM研究

Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study.
PubMed 文献 · JACC Cardiovasc Imaging · 2018-06-13

PARADIGM前瞻性多国注册研究纳入无冠心病史、接受≥2年间期冠状动脉CT血管造影的连续患者,定量分析斑块狭窄程度、斑块体积、成分及高危斑块特征。服用他汀者整体斑块体积进展较慢、钙化体积进展更快,非钙化体积进展和新发高危斑块特征年发生率更低,但狭窄进展至>50%的比例无差异。

要点

  • 服用他汀者整体斑块体积年进展较未服用者慢(1.76%/年 vs 2.04%/年,p=0.002)。
  • 服用他汀者钙化斑块体积年进展更快(1.27%/年 vs 0.98%/年,p<0.001)。
  • 服用他汀者非钙化斑块体积年进展及新发高危斑块特征年发生率更低(p<0.001)。

核心结论

  • 他汀与整体冠状动脉粥样硬化体积进展较慢相关,伴斑块钙化增加和高危斑块特征减少;他汀未影响冠状动脉病变狭窄严重程度百分比的进展,但诱导了斑块表型转化。

研究设计与样本

  • 前瞻性多国注册研究,纳入无冠心病史、接受间期≥2年系列冠状动脉CT血管造影的连续患者;共1255例患者(年龄60±9岁,57%男性),未服用他汀组474例评估1079个冠状动脉病变,服用他汀组781例评估2496个冠状动脉病变。

关键影像表现/征象

  • 高危斑块定义为低衰减斑块、正性动脉重构或点状钙化中≥2项特征并存。
  • 服用他汀者整体斑块体积年进展较未服用者慢(1.76±2.40%/年 vs 2.04±2.37%/年,p=0.002)。
  • 服用他汀者钙化斑块体积年进展较未服用者快(1.27±1.54%/年 vs 0.98±1.27%/年,p<0.001)。
  • 服用他汀者非钙化斑块体积年进展较未服用者低(0.49±2.39%/年 vs 1.06±2.42%/年,p<0.001)。
  • 服用他汀者新发高危斑块特征年发生率较未服用者低(0.9%/年 vs 1.6%/年,p<0.001)。

诊断标准与关键数值

  • 定量分析指标包括直径狭窄百分比(%DS)、斑块体积百分比(PAV)、斑块成分及高危斑块(HRP)存在情况。
  • 进展至>50%直径狭窄的比例在服用他汀者与未服用者间无差异(1.0% vs 1.4%,p>0.05)。
  • 他汀与年化整体PAV进展超过中位数风险降低21%相关,与高危斑块形成风险降低35%相关。

临床应用与阅片要点

  • 系列冠状动脉CT血管造影可定量随访斑块体积、成分及高危特征变化。
  • 服用他汀者的斑块进展可表现为整体体积进展减慢而钙化体积进展加快,判读时需结合用药状态。
  • 新发高危斑块特征年发生率在服用他汀者中更低(0.9%/年 vs 1.6%/年)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study sought to describe the impact of statins on individual coronary atherosclerotic plaques.

BACKGROUND: Although statins reduce the risk of major adverse cardiovascular events, their long-term effects on coronary atherosclerosis remain unclear.

METHODS: We performed a prospective, multinational study consisting of a registry of consecutive patients without history of coronary artery disease who underwent serial coronary computed tomography angiography at an interscan interval of ≥2 years. Atherosclerotic plaques were quantitatively analyzed for percent diameter stenosis (%DS), percent atheroma volume (PAV), plaque composition, and presence of high-risk plaque (HRP), defined by the presence of ≥2 features of low-attenuation plaque, positive arterial remodeling, or spotty calcifications.

RESULTS: Among 1,255 patients (60 ± 9 years of age; 57% men), 1,079 coronary artery lesions were evaluated in statin-naive patients (n = 474), and 2,496 coronary artery lesions were evaluated in statin-taking patients (n = 781). Compared with lesions in statin-naive patients, those in statin-taking patients displayed a slower rate of overall PAV progression (1.76 ± 2.40% per year vs. 2.04 ± 2.37% per year, respectively; p = 0.002) but more rapid progression of calcified PAV (1.27 ± 1.54% per year vs. 0.98 ± 1.27% per year, respectively; p < 0.001). Progression of noncalcified PAV and annual incidence of new HRP features were lower in lesions in statin-taking patients (0.49 ± 2.39% per year vs. 1.06 ± 2.42% per year and 0.9% per year vs. 1.6% per year, respectively; all p < 0.001). The rates of progression to >50% DS were not different (1.0% vs. 1.4%, respectively; p > 0.05). Statins were associated with a 21% reduction in annualized total PAV progression above the median and 35% reduction in HRP development.

CONCLUSIONS: Statins were associated with slower progression of overall coronary atherosclerosis volume, with increased plaque calcification and reduction of high-risk plaque features. Statins did not affect the progression of percentage of stenosis severity of coronary artery lesions but induced phenotypic plaque transformation. (Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging [PARADIGM]; NCT02803411).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Lee SE, Chang HJ, Sung JM, et al. Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study. JACC Cardiovasc Imaging. 2018. PMID: 29909109. doi:10.1016/j.jcmg.2018.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。